HIV合并HCV感染者的丙肝微消除:治疗扩大伴随发病率与患病率下降
本研究为在澳大利亚墨尔本实施的co-EC干预试验,2016至2018年向HIV/HCV合并感染者提供直接抗病毒药物治疗。研究显示初级保健与专科治疗的持续病毒学应答率均为98%,且2012至2019年间HIV阳性男男性行为者中HCV病毒血症患病率下降83%、发病率年降25%,提示治疗扩大可实现HCV微消除。
要点
- 初级保健中非专科医生提供HCV治疗的有效性与专科治疗相当。
- 治疗扩大期间,HIV阳性GBM中HCV病毒血症患病率下降83%。
- HCV发病率从2012年1.7/100人年降至2019年0.5/100人年。
核心结论
- 非专科医生提供的高效治疗证明在该人群中扩大治疗规模是可行的。
- GBM中HCV发病率和患病率的大幅下降为HCV微消除提供了概念验证。
研究设计与样本
- co-EC研究是一项在澳大利亚墨尔本2016至2018年实施的干预试验,提供HCV直接抗病毒治疗。
- 从初级和三级保健服务机构前瞻性招募HCV/HIV合并感染者,共200例入组,其中186例在研究期间启动治疗。
- 采用全州链接监测系统测量HCV病毒血症患病率及HCV抗体/病毒血症发病率。
主要发现
- 初级保健的持续病毒学应答率为98%(95%CI 93%-100%),与三级保健的98%(95%CI 86%-100%)无差异。
- 抗-HCV阳性者中,病毒血症患病率在研究期间下降83%(2016年54%降至2019年9%)。
临床怎么用
- 可在初级保健中由非专科医生为HIV/HCV合并感染者提供直接抗病毒治疗,有效性高。
- 通过治疗扩大可显著降低GBM中HCV患病率和发病率,支持微消除策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gay and bisexual men (GBM) are a key population affected by human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection. We aimed to measure HCV treatment effectiveness and to determine the population impact of treatment scale-up on HCV prevalence and incidence longitudinally among GBM. METHODS: The co-EC Study (Enhancing Care and Treatment Among HCV/HIV Coinfected Individuals to Eliminate Hepatitis C Transmission) was an implementation trial providing HCV direct-acting antiviral treatment in Melbourne, Australia, during 2016-2018. Individuals with HCV/HIV coinfection were prospectively enrolled from primary and tertiary care services. HCV viremic prevalence and HCV antibody/viremic incidence were measured using a statewide, linked, surveillance system. RESULTS: Among 200 participants recruited, 186 initiated treatment during the study period. Sustained virological response in primary care (98% [95% confidence interval {CI}, 93%-100%]) was not different to tertiary care (98% [95% CI, 86%-100%]). From 2012 to 2019, between 2434 and 3476 GBM with HIV infection attended our primary care sites annually, providing 13 801 person-years of follow-up; 50%-60% received an HCV test annually, and 10%-14% were anti-HCV positive. Among those anti-HCV positive, viremic prevalence declined 83% during the study (54% in 2016 to 9% in 2019). HCV incidence decreased 25% annually from 1.7/100 person-years in 2012 to 0.5/100 person-years in 2019 (incidence rate ratio, 0.75 [95% CI, .68-.83]; P < .001). CONCLUSIONS: High treatment effectiveness by nonspecialists demonstrates the feasibility of treatment scale-up in this population. Substantial declines in HCV incidence and prevalence among GBM provides proof-of-concept for HCV microelimination. CLINICAL TRIALS REGISTRATION: NCT02786758.
引用
- Doyle JS, van Santen DK, Iser D, et al. Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial. Clin Infect Dis. 2021. PMID: 33010149. doi:10.1093/cid/ciaa1500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。